Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial to Assess the Immunogenicity and Safety of the ChAdOx1 RVF Vaccine Against Rift Valley Fever in Adults in Kenya

NCT06799234 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT06799234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06799234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial to Assess the Immunogenicity and Safety of the ChAdOx1 RVF Vaccine Against Rift Valley Fever in Adults in Kenya
Lead sponsor
University of Oxford
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 8, 2025
Completion date
March 31, 2027
Enrollment
240 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rift valley fever